PKNOX2

Across TCGA pan-cancer cohorts, PKNOX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PKNOX2 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PKNOX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PKNOX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, OV, and SARC are the cancer types where PKNOX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.160	0.710	<.001	33	view →
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
SARC	DFS	Median	All	0.158	0.613	.005	6	view →
PRAD	DFS	Median	All	0.504	0.936	<.001	6	view →
UCEC	OS	Median	All	0.974	0.864	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PKNOX2–HNSC (OS)

Open the HNSC breakdown →